---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028192"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:47:06.632907+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq notifies Avalo Therapeutics of bid price and MVLS non-compliance

## Summary
- Bid price below $1.00 for 30 consecutive days; MVLS below $35M.
- Company has 180 days until Feb 5, 2024 to regain compliance.
- If not cured, may be eligible for additional 180-day period with reverse split plan.
- No immediate impact on listing; stock continues trading under AVTX.
- Company evaluating options; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001628280-23-028192
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023028192/0001628280-23-028192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023028192/avtx-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028192
- JSON: https://secwatch.observer/filing/0001628280-23-028192.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028192.txt

## Key facts
- Listing & Compliance Notices
  Avalo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: August 8, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Avalo Therapeutics, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market pursuant to Na
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023028192/0001628280-23-028192-index.htm
- Listing & Compliance Notices
  Avalo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: August 8, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Avalo Therapeutics, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market pursuant to Na
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023028192/0001628280-23-028192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.